ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Glioblastoma (GBM) creates an immunosuppressive environment that allows tumor growth. Myeloid derived suppressor cells (MDSCs) mediate immunosuppression in GBMs. MDSCs are up-regulated in the blood of GBM patients. We have developed a novel strategy to target GBM immunosuppression using...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Peereboom, David, Lathia, Justin, Alban, Tyler, Mohammadi, Alireza, Ahluwalia, Manmeet, Brewer, Cathy, Vogelbaum, Michael
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216163/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.044
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料